Global Fatty Acid Oxidation Disorder Market

Fatty Acid Oxidation Disorder Comprehensive Study by Supplement Type (L-carnitine, L-carnitine, Medium Chain Triglyceride Oil), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores), Medication Route of Administration (Oral, Intravenous), Disorder Type (Carnitine Uptake Defect (CUD), Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD), Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD), Trifunctional Protein Deficiency (TFP), Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD)) Players and Region - Global Market Outlook to 2030

Fatty Acid Oxidation Disorder Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fatty Acid Oxidation Disorder
Fatty acid oxidation disorders are rare health conditions that affect how a body breaks down fat. They are categorized as under hereditary disorders. The body is unable to produce or use particle enzyme, which is needed for fatty acid oxidation, in fatty acid oxidation disorder. The lack of enzymes prevents fatty acids from being broken down, causing them to build up in the liver and other internal organs. Fatty acid oxidation disease occurs when the liver and muscles are unable to obtain energy from fatty acids. In the fatty acid oxidation disorder market, hospital pharmacies have the largest share of the distribution channel. With increased consumer penetration in the fatty acid oxidation disorder market, online pharmacies will see a substantial increase in demand.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The FAOD market is poised for significant growth in the coming years, driven by rising awareness, improved diagnostics, and the development of novel therapies. Companies that can cater to the diverse needs of FAOD patients, personalize treatment approaches, and ensure access to specialized nutrition will be well-positioned to succeed in this evolving market. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Biosynth AG (Switzerland), Daiichi Sankyo Ltd. (Japan), Northeast Pharmaceutical Group Co., Ltd. (China), Merck KGaA (Germany), Mylan Laboratories Limited (United States), AminoScience LLC (United States), Chengda Pharmaceuticals Co. Ltd. (China), Sigma-Tau Pharmaceuticals (United States), Bedford Laboratories (United States) and Spectrum Chemicals and Laboratory Products, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Fatty Acid Oxidation Disorder market by and Region.



On the basis of geography, the market of Fatty Acid Oxidation Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Supplement Type, the sub-segment i.e. L-carnitine will boost the Fatty Acid Oxidation Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Fatty Acid Oxidation Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication Route of Administration , the sub-segment i.e. Oral will boost the Fatty Acid Oxidation Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder Type, the sub-segment i.e. Carnitine Uptake Defect (CUD) will boost the Fatty Acid Oxidation Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Prevalence Newborn screening

Market Growth Drivers:
Rise In the Prevalence or Rare and Genetic Body Disorders and Increasing Awareness about Health among People

Challenges:
Lack of Awareness About Therapeutic Options Available For Rare Disorders

Restraints:
Stringent Regulatory Requirement For Drug Approval

Opportunities:
Increased Investment in Research and Development of Rare Body Disorder

Market Leaders and their expansionary development strategies
In September 2023, A study published in The Lancet Child & Adolescent Health highlights the importance of early diagnosis and multidisciplinary care for children with FAODs.
In April 2023, The US Food and Drug Administration (FDA) approves the first oral medication for carnitine palmitoyltransferase II (CPT II) deficiency, a common form of FAOD.


Key Target Audience
Manufacturers of Fatty Acid Oxidation Drug, Suppliers of Fatty Acid Oxidation Drug, Wholesalers, Distributors and Retailers of Fatty Acid Oxidation Drug, Pharmaceutical Industry and Regulatory Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Supplement Type
  • L-carnitine
  • L-carnitine
  • Medium Chain Triglyceride Oil

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores

By Medication Route of Administration
  • Oral
  • Intravenous

By Disorder Type
  • Carnitine Uptake Defect (CUD)
  • Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD)
  • Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD)
  • Trifunctional Protein Deficiency (TFP)
  • Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise In the Prevalence or Rare and Genetic Body Disorders
      • 3.2.2. Increasing Awareness about Health among People
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness About Therapeutic Options Available For Rare Disorders
    • 3.4. Market Trends
      • 3.4.1. Rising Prevalence Newborn screening
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fatty Acid Oxidation Disorder, by Supplement Type, Distribution Channel, Medication Route of Administration , Disorder Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fatty Acid Oxidation Disorder (Value)
      • 5.2.1. Global Fatty Acid Oxidation Disorder by: Supplement Type (Value)
        • 5.2.1.1. L-carnitine
        • 5.2.1.2. L-carnitine
        • 5.2.1.3. Medium Chain Triglyceride Oil
      • 5.2.2. Global Fatty Acid Oxidation Disorder by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Stores
      • 5.2.3. Global Fatty Acid Oxidation Disorder by: Disorder Type (Value)
        • 5.2.3.1. Carnitine Uptake Defect (CUD)
        • 5.2.3.2. Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD)
        • 5.2.3.3. Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD)
        • 5.2.3.4. Trifunctional Protein Deficiency (TFP)
        • 5.2.3.5. Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD)
      • 5.2.4. Global Fatty Acid Oxidation Disorder Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Fatty Acid Oxidation Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biosynth AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Daiichi Sankyo Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Northeast Pharmaceutical Group Co., Ltd. (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan Laboratories Limited (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AminoScience LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Chengda Pharmaceuticals Co. Ltd. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sigma-Tau Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bedford Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Spectrum Chemicals and Laboratory Products, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Fatty Acid Oxidation Disorder Sale, by Supplement Type, Distribution Channel, Medication Route of Administration , Disorder Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fatty Acid Oxidation Disorder (Value)
      • 7.2.1. Global Fatty Acid Oxidation Disorder by: Supplement Type (Value)
        • 7.2.1.1. L-carnitine
        • 7.2.1.2. L-carnitine
        • 7.2.1.3. Medium Chain Triglyceride Oil
      • 7.2.2. Global Fatty Acid Oxidation Disorder by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Stores
      • 7.2.3. Global Fatty Acid Oxidation Disorder by: Disorder Type (Value)
        • 7.2.3.1. Carnitine Uptake Defect (CUD)
        • 7.2.3.2. Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD)
        • 7.2.3.3. Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD)
        • 7.2.3.4. Trifunctional Protein Deficiency (TFP)
        • 7.2.3.5. Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD)
      • 7.2.4. Global Fatty Acid Oxidation Disorder Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fatty Acid Oxidation Disorder: by Supplement Type(USD Million)
  • Table 2. Fatty Acid Oxidation Disorder L-carnitine , by Region USD Million (2018-2023)
  • Table 3. Fatty Acid Oxidation Disorder L-carnitine , by Region USD Million (2018-2023)
  • Table 4. Fatty Acid Oxidation Disorder Medium Chain Triglyceride Oil , by Region USD Million (2018-2023)
  • Table 5. Fatty Acid Oxidation Disorder: by Distribution Channel(USD Million)
  • Table 6. Fatty Acid Oxidation Disorder Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 7. Fatty Acid Oxidation Disorder Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 8. Fatty Acid Oxidation Disorder Online Stores , by Region USD Million (2018-2023)
  • Table 9. Fatty Acid Oxidation Disorder: by Disorder Type(USD Million)
  • Table 10. Fatty Acid Oxidation Disorder Carnitine Uptake Defect (CUD) , by Region USD Million (2018-2023)
  • Table 11. Fatty Acid Oxidation Disorder Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD) , by Region USD Million (2018-2023)
  • Table 12. Fatty Acid Oxidation Disorder Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD) , by Region USD Million (2018-2023)
  • Table 13. Fatty Acid Oxidation Disorder Trifunctional Protein Deficiency (TFP) , by Region USD Million (2018-2023)
  • Table 14. Fatty Acid Oxidation Disorder Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD) , by Region USD Million (2018-2023)
  • Table 15. South America Fatty Acid Oxidation Disorder, by Country USD Million (2018-2023)
  • Table 16. South America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 17. South America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 18. South America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 19. South America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 20. Brazil Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 21. Brazil Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 23. Brazil Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 24. Argentina Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 25. Argentina Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 27. Argentina Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 28. Rest of South America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 29. Rest of South America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 31. Rest of South America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 32. Asia Pacific Fatty Acid Oxidation Disorder, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 34. Asia Pacific Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 35. Asia Pacific Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 36. Asia Pacific Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 37. China Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 38. China Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 40. China Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 41. Japan Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 42. Japan Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 44. Japan Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 45. India Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 46. India Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 48. India Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 49. South Korea Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 50. South Korea Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 52. South Korea Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 53. Taiwan Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 54. Taiwan Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 56. Taiwan Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 57. Australia Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 58. Australia Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 60. Australia Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 65. Europe Fatty Acid Oxidation Disorder, by Country USD Million (2018-2023)
  • Table 66. Europe Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 67. Europe Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 68. Europe Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 69. Europe Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 70. Germany Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 71. Germany Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 73. Germany Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 74. France Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 75. France Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 77. France Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 78. Italy Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 79. Italy Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 81. Italy Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 82. United Kingdom Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 83. United Kingdom Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 85. United Kingdom Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 86. Netherlands Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 87. Netherlands Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 89. Netherlands Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 90. Rest of Europe Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 91. Rest of Europe Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 93. Rest of Europe Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 94. MEA Fatty Acid Oxidation Disorder, by Country USD Million (2018-2023)
  • Table 95. MEA Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 96. MEA Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 97. MEA Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 98. MEA Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 99. Middle East Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 100. Middle East Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 102. Middle East Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 103. Africa Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 104. Africa Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 106. Africa Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 107. North America Fatty Acid Oxidation Disorder, by Country USD Million (2018-2023)
  • Table 108. North America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 109. North America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 110. North America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 111. North America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 112. United States Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 113. United States Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 115. United States Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 116. Canada Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 117. Canada Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 119. Canada Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 120. Mexico Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2018-2023)
  • Table 121. Mexico Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2018-2023)
  • Table 123. Mexico Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Fatty Acid Oxidation Disorder: by Supplement Type(USD Million)
  • Table 135. Fatty Acid Oxidation Disorder L-carnitine , by Region USD Million (2025-2030)
  • Table 136. Fatty Acid Oxidation Disorder L-carnitine , by Region USD Million (2025-2030)
  • Table 137. Fatty Acid Oxidation Disorder Medium Chain Triglyceride Oil , by Region USD Million (2025-2030)
  • Table 138. Fatty Acid Oxidation Disorder: by Distribution Channel(USD Million)
  • Table 139. Fatty Acid Oxidation Disorder Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 140. Fatty Acid Oxidation Disorder Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 141. Fatty Acid Oxidation Disorder Online Stores , by Region USD Million (2025-2030)
  • Table 142. Fatty Acid Oxidation Disorder: by Disorder Type(USD Million)
  • Table 143. Fatty Acid Oxidation Disorder Carnitine Uptake Defect (CUD) , by Region USD Million (2025-2030)
  • Table 144. Fatty Acid Oxidation Disorder Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (LCHAD) , by Region USD Million (2025-2030)
  • Table 145. Fatty Acid Oxidation Disorder Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCAD) , by Region USD Million (2025-2030)
  • Table 146. Fatty Acid Oxidation Disorder Trifunctional Protein Deficiency (TFP) , by Region USD Million (2025-2030)
  • Table 147. Fatty Acid Oxidation Disorder Very-Long-Chain Acyl-Coa Dehydrogenase Deficiency (VLCAD) , by Region USD Million (2025-2030)
  • Table 148. South America Fatty Acid Oxidation Disorder, by Country USD Million (2025-2030)
  • Table 149. South America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 150. South America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 151. South America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 152. South America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 153. Brazil Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 154. Brazil Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 155. Brazil Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 156. Brazil Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 157. Argentina Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 158. Argentina Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 159. Argentina Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 160. Argentina Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 161. Rest of South America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 162. Rest of South America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 163. Rest of South America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 164. Rest of South America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 165. Asia Pacific Fatty Acid Oxidation Disorder, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 167. Asia Pacific Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 168. Asia Pacific Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 169. Asia Pacific Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 170. China Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 171. China Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 172. China Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 173. China Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 174. Japan Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 175. Japan Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 176. Japan Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 177. Japan Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 178. India Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 179. India Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 180. India Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 181. India Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 182. South Korea Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 183. South Korea Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 184. South Korea Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 185. South Korea Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 186. Taiwan Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 187. Taiwan Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 188. Taiwan Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 189. Taiwan Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 190. Australia Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 191. Australia Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 192. Australia Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 193. Australia Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 198. Europe Fatty Acid Oxidation Disorder, by Country USD Million (2025-2030)
  • Table 199. Europe Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 200. Europe Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 201. Europe Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 202. Europe Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 203. Germany Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 204. Germany Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 205. Germany Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 206. Germany Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 207. France Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 208. France Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 209. France Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 210. France Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 211. Italy Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 212. Italy Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 213. Italy Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 214. Italy Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 215. United Kingdom Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 216. United Kingdom Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 217. United Kingdom Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 218. United Kingdom Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 219. Netherlands Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 220. Netherlands Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 221. Netherlands Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 222. Netherlands Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 223. Rest of Europe Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 224. Rest of Europe Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 225. Rest of Europe Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 226. Rest of Europe Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 227. MEA Fatty Acid Oxidation Disorder, by Country USD Million (2025-2030)
  • Table 228. MEA Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 229. MEA Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 230. MEA Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 231. MEA Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 232. Middle East Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 233. Middle East Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 234. Middle East Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 235. Middle East Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 236. Africa Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 237. Africa Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 238. Africa Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 239. Africa Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 240. North America Fatty Acid Oxidation Disorder, by Country USD Million (2025-2030)
  • Table 241. North America Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 242. North America Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 243. North America Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 244. North America Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 245. United States Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 246. United States Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 247. United States Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 248. United States Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 249. Canada Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 250. Canada Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 251. Canada Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 252. Canada Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 253. Mexico Fatty Acid Oxidation Disorder, by Supplement Type USD Million (2025-2030)
  • Table 254. Mexico Fatty Acid Oxidation Disorder, by Distribution Channel USD Million (2025-2030)
  • Table 255. Mexico Fatty Acid Oxidation Disorder, by Medication Route of Administration USD Million (2025-2030)
  • Table 256. Mexico Fatty Acid Oxidation Disorder, by Disorder Type USD Million (2025-2030)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fatty Acid Oxidation Disorder: by Supplement Type USD Million (2018-2023)
  • Figure 5. Global Fatty Acid Oxidation Disorder: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Fatty Acid Oxidation Disorder: by Disorder Type USD Million (2018-2023)
  • Figure 7. South America Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 8. Asia Pacific Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 9. Europe Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 10. MEA Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 11. North America Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 12. Global Fatty Acid Oxidation Disorder share by Players 2023 (%)
  • Figure 13. Global Fatty Acid Oxidation Disorder share by Players (Top 3) 2023(%)
  • Figure 14. Global Fatty Acid Oxidation Disorder share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Biosynth AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Biosynth AG (Switzerland) Revenue: by Geography 2023
  • Figure 18. Daiichi Sankyo Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Daiichi Sankyo Ltd. (Japan) Revenue: by Geography 2023
  • Figure 20. Northeast Pharmaceutical Group Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 21. Northeast Pharmaceutical Group Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 22. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 24. Mylan Laboratories Limited (United States) Revenue, Net Income and Gross profit
  • Figure 25. Mylan Laboratories Limited (United States) Revenue: by Geography 2023
  • Figure 26. AminoScience LLC (United States) Revenue, Net Income and Gross profit
  • Figure 27. AminoScience LLC (United States) Revenue: by Geography 2023
  • Figure 28. Chengda Pharmaceuticals Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 29. Chengda Pharmaceuticals Co. Ltd. (China) Revenue: by Geography 2023
  • Figure 30. Sigma-Tau Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sigma-Tau Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 32. Bedford Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bedford Laboratories (United States) Revenue: by Geography 2023
  • Figure 34. Spectrum Chemicals and Laboratory Products, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Spectrum Chemicals and Laboratory Products, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Fatty Acid Oxidation Disorder: by Supplement Type USD Million (2025-2030)
  • Figure 37. Global Fatty Acid Oxidation Disorder: by Distribution Channel USD Million (2025-2030)
  • Figure 38. Global Fatty Acid Oxidation Disorder: by Disorder Type USD Million (2025-2030)
  • Figure 39. South America Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 40. Asia Pacific Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 41. Europe Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 42. MEA Fatty Acid Oxidation Disorder Share (%), by Country
  • Figure 43. North America Fatty Acid Oxidation Disorder Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Biosynth AG (Switzerland)
  • Daiichi Sankyo Ltd. (Japan)
  • Northeast Pharmaceutical Group Co., Ltd. (China)
  • Merck KGaA (Germany)
  • Mylan Laboratories Limited (United States)
  • AminoScience LLC (United States)
  • Chengda Pharmaceuticals Co. Ltd. (China)
  • Sigma-Tau Pharmaceuticals (United States)
  • Bedford Laboratories (United States)
  • Spectrum Chemicals and Laboratory Products, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 206 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fatty Acid Oxidation Disorder Market Quantitative research analysis
Global Fatty Acid Oxidation Disorder Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Biosynth AG (Switzerland), Daiichi Sankyo Ltd. (Japan), Northeast Pharmaceutical Group Co., Ltd. (China), Merck KGaA (Germany), Mylan Laboratories Limited (United States), AminoScience LLC (United States), Chengda Pharmaceuticals Co. Ltd. (China), Sigma-Tau Pharmaceuticals (United States), Bedford Laboratories (United States) and Spectrum Chemicals and Laboratory Products, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Prevalence Newborn screening" is seen as one of major influencing trends for Fatty Acid Oxidation Disorder Market during projected period 2023-2030.
The Fatty Acid Oxidation Disorder market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fatty Acid Oxidation Disorder Market Report?

Have a Query? Click Here

Other Related Reports

Antiviral Combination Therapies Comprehensive Study by Type (Branded, Generic), Route of Administration (Oral, Intravenous), Indication (HIV, Hepatitis, Others), Drug Combination (NRTI/NNRTI, Integra...
$ 3450
Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) ...
$ 3500
Acute Agitation and Aggression Treatment Comprehensive Study by Therapy (Chemotherapy, Cognitive Behavioural Therapy (CBT), Others), Route of Administration (Oral, Sublingual, Intramuscular, Others),...
$ 3750
Dyslexia Treatment Comprehensive Study by Type (Phonological Dyslexia, Surface Dyslexia), Treatment (Drug Class, Tools, Educational Techniques), End-users (Hospitals, Home Care, Others), Distribution...
$ 3450
Deep Vein Thrombosis Treatment Comprehensive Study by Type (Medication, Devices, Surgery), Application (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, Other), End Users (Hospitals, Ho...
$ 3750
Veterinary Artificial Insemination Comprehensive Study by Type (Equipment (Semen Applicator, Insemination Gun, Others), Consumables (Sheath, Lubricant, Glove, Heat Detector, Others), Accessories), An...
$ 3650